Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels

Christie M. Ballantyne, Ethan J. Podet, Wolfgang P. Patsch, Yadollah Harati, Vicki Appel, Antonio M. Gotto, James B. Young

Research output: Contribution to journalArticlepeer-review

252 Scopus citations


Accelerated atherosclerosis is a leading cause of death in long-term survivors of heart and renal transplantation and may be exacerbated by the frequent occurrence of posttransplant hyperlipidemia. Attempts to define the mechanism for hyperlipidemia in transplant recipients are confounded by dramatic changes in metabolism and nutritional status after transplantation, as well as by treatment with multiple immunosuppressive and antihypertensive drugs. To avoid these pitfalls and to determine if cyclosporine alone adversely affects lipid levels, we measured lipoprotein levels in a prospective, double-blind, randomized, placebo-controlled trial of cyclosporine in 36 men with amyotrophic lateral sclerosis. Plasma total cholesterol, triglyceride, high-density lipoprotein cholesterol, and apolipoprotein B levels were measured at baseline, 2 weeks, 1 month, and 2 months. Significant increases of 21% in total cholesterol, 31% in low-density lipoprotein cholesterol, and 12% in apolipoprotein B levels occurred only in the cyclosporine group. Cyclosporine therapy alone adversely affects plasma lipoprotein levels by increasing total cholesterol levels, primarily due to an increase in low-density lipoprotein cholesterol level.

Original languageEnglish (US)
Pages (from-to)53-56
Number of pages4
JournalJournal of the American Medical Association
Issue number1
StatePublished - Jul 7 1989

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Effects of Cyclosporine Therapy on Plasma Lipoprotein Levels'. Together they form a unique fingerprint.

Cite this